Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yunzhi Liver Tai capsules are a botanical pharmaceutical product derived from the medicinal mushroom *Coriolus versicolor* (also known as Yunzhi or Turkey Tail). Developed and manufactured by Shenghua Pharmaceutical Technology, the capsules contain active polysaccharopeptides (PSP) and polysaccharides (PSK) that function as biological response modifiers. The drug is primarily indicated for the treatment of chronic hepatitis and the improvement of immune function in patients with weakened immunity, including those undergoing cancer treatments. Its mechanism involves the stimulation of T-lymphocytes, natural killer (NK) cells, and macrophages, alongside hepatoprotective effects that help stabilize liver enzyme levels and promote liver tissue repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yunzhi Liver Tai capsules.